Slide 1: Investor Presentation
Investor Presentation September 30, 2025
Slide 2: Cautionary Statement
CAUTIONARY STATEMENT This document is current as of September 30, 2025, except where Financial outlook involves statements about the Company's prospective calculated in accordance with IFRS is net income (loss). The most directly otherwise stated. The information contained in this presentation is pr
Slide 3: Q4 F25 Highlights
Q4 F25 Highlights In millions unless otherwise indicated +79% +85% +69% $80.1 $30.6 $9.8 $44.7 $16.5 $5.9 Q4 F24 Q4 F25 Q4 F24 Q4 F25 Q4 F24 Q4 F25 Record Net Revenue Record Adjusted Six-Year High Gross Profit1 Adjusted EBITDA1 1. Adjusted gross margin and adjusted EBITDA are non-IFRS financial meas
Slide 4: Mission and Vision
MISSION A cannabis friendly future. VISION, To be a respected global leader, meetin the evolving needs of the consumer of tomorrow. INTEGRITY fmm | pm | ACCOUNTABILITY CURIOSITY TEAMWORK ORGANIGRAM GLOBAL
Slide 5: Canadian Roots. Naturally Global.
Canadian Roots. Naturally Global. 12 YEARS OF WORLD CLASS INNOVATION GLOBAL RAPID RESPONSIBLE CAPABILITIES TRAILBLAZER STRATEGIC INTERNATIONAL LEADERSHIP INVESTOR EXPANSION Founded in 2013, Organigram operates five Organigram is a leader Organigram has received over Organigram has achieved Organigra
Slide 6: Canada's #1 LP in market
PRE-ROLLS MILLED (including IPRs) CONCENTRATES FLOWER Canada’s #1 #1 #1 #1 LP in market share1 VAPES FLOWER (including milled) GUMMIES RECREATIONAL MARKET #1 #3 #3 1. Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of September 30, 2025.
Slide 7: Coast to Coast Leadership by market share
Coast to Coast Leadership by market share # 1 WESTERN CANADA # 1 EASTERN CANADA 1 # CENTRAL CANADA Moncton Facility Winnipeg Lac-Supérieur Facility Facility London & Aylmer Facilities Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of September 30, 2025 (formerly Mot
Slide 8: Current Global Distribution
Current Global Distribution 1. Showing product availability as of December 11, 2025.
Slide 9: State-of-the-art Facilities
State-of-the-art Facilities Canada’s largest indoor cultivation Winnipeg, MB Aylmer, ON London, ON Lac-Supérieur, QC Moncton, NB • Edibles facility with Advanced capabilities & Centralized distribution hub to • Producing hang-dried, hand- • Three-tiered, modular, strain-specific automated cutting-ed
Slide 10: Portfolio of Beloved Brands
Portfolio PREMIUM of Beloved Brands MAINSTREAM Delivering strong coverage across all segments and categories FLOWER MILLED PRE-ROLLS INFUSED PRE-ROLLS VAPES BEVERAGES VALUE EDIBLES HASH CONCENTRATES OILS
Slide 11: Brand highlights
• Premium innovation brand • Award-winning mainstream brand with • #1 Canadian vape brand by market share1 • First Organigram brand to launch broad category coverage and the • Portfolio includes IPRs, and other 2.0 proprietary FASTTM products which highest repurchase rate in the Canadian products in
Slide 12: US Portfolio
US PORTFOLIO • Gummy brand offering low THC + • Award winning sparkling juices and • Value-priced soda brand with top selling functional ingredients like caffeine, lemonades flavours like cola, lemon-lime and cream chamomile extract and l-theanine to • Supports the arts community soda target specifi
Slide 13: Fiscal 2025 Acquisitions
Fiscal 2025 Acquisitions Completed December 2024 Completed March 2025 Revenue Expansion Drives Long-Term Margin Improvement Deal Rationale & Key Updates Stronger • Fast tracked Organigram’s entry into the rapidly-growing Fixed cost Economies absorption market cannabinoid beverages category and U.S.
Slide 14: Strategic Investments from BAT
Strategic Investments from BAT: 2024 Over $345 Million Invested $125 Million 2021 • Creation of strategic investment pool named Jupiter, funded with $83.1 million $221 Million • $41.5 million proceeds for general corporate purposes • Final $41.5 million tranche closed in February 2025 • Establish
Slide 15: Investment Pool
Priority Investment Pillars Investment Pool Geographies • • U.S. Emerging global markets The $83.1 million Jupiter investment Categories & Tech pool targets investments in emerging • • Non-combustible inhalation Edibles • Beverages cannabis opportunities • All potential investments are made in align
Slide 16: Investments
Investments GERMANY AND EUROPE MANUFACTURING & FORMULATION SEED-BASED TECHNOLOGY • $21 million investment into German cannabis • U.S.$2 million investment into • Up to US$8 million investment (U.S$7 million leader Sanity Group to establish foothold in U.S.-based OBX.1 invested to-date) into U.S.-bas
Slide 17: Seeds: More Robust and Uniform
Seeds: More Robust and Uniform Uniformity and Robustness of Seed Grow Clones Seeds
Slide 18: Fiscal 2025 Highlights
Fiscal 2025 Highlights FISCAL 2025 FINANCIAL Q4 FISCAL 2025 FINANCIAL HIGHLIGHTS HIGHLIGHTS • Record Gross Revenue: $403.0 million (+63% year-over- • Record Gross Revenue: $123.3 million (+76% year-over-year). year). • Record Net Revenue: $80.1 million (+79% year-over-year). • Record Net Revenue: $2
Slide 19: Fiscal 2025 Company Highlights
FISCAL 2025 COMPANY HIGHLIGHTS • #1 Market Share in Canada: Maintained recreational market leadership across Canada with 11.9% share of the market as of the end of Fiscal 2025.1 • Record International Revenue: $26.3 million (+173% year-over-year). • Fast Acting Soluble Technology (FASTTM): Launched
Slide 20: Increasing International Sales
Increasing International Sales • Strong international sales trajectory • Continue to await EU-GMP certification, expected to increase sales and margins • Diversified customer base • Introduction of sales from entry into U.S. beverage market1 1 In November 2025, the U.S. enacted the Continuing Approp
Slide 21: Revenue and Margins (millions)
Revenue and Margins (millions) 38% 36% 37% 34% 33% 33% $123.3 31% 31% $110.2 $102.8 $69.9 $63.6 $66.8 $56.3 $57.4 $80.1 $65.6 $70.8 $44.7 $42.7 $37.6 $41.1 $36.5 $24.2 $30.6 $16.5 $21.9 $11.2 $11.6 $14.6 $14.3 Q1 F24 Q2 F24 Q3 F24 Q4 F24 Q1 F25 Q2 F25 Q3 F25 Q4 F25 1 1 Net Revenue Gross Revenue Adj.
Slide 22: Adjusted EBITDA (millions)
Adjusted EBITDA1 (millions) $9.8 $5.9 $5.7 $4.9 $3.5 $1.4 $0.1 -$1.0 Q1 F24 Q2 F24 Q3 F24 Q4 F24 Q1 F25 Q2 F25 Q3 F25 Q4 F25 1. Adjusted EBITDA is a non-IFRS financial measures not defined by and does not have any standardized meanings under International Financial Reporting Standards ("IFRS"), as i
Slide 23: Balance Sheet
Balance Sheet AS OF END OF Q4 Fiscal 2025: $84.4 million $28.2 million Total cash Unrestricted cash (including restricted cash & short-term investments) $59 million1 No material Jupiter Pool debt 1. The Jupiter pool has $59 million available for international strategic investments, of which $10 mill
Slide 24: Q4 FY25 Select Financial Metrics
Q4 FY25 Select Financial Metrics In 000’s unless otherwise indicated Select Key Financial Metrics (in $000s unless otherwise indicated) Q4-2025 Q4-2024 % Change Gross revenue 123,250 69,877 76% Excise taxes (43,189) (25,179) 72% Net revenue 80,061 44,698 79% Cost of sales 52,053 30,907 68% Gross mar
Slide 25: Q4 FY25 Select Balance Sheet Metrics
Q4 FY25 Select Balance Sheet Metrics In 000’s unless otherwise indicated Select Balance Sheet Metrics (in $000s) SEPT 30, 2025 SEPT 30, 2024 % Change Cash & short-term investments (including restricted cash) 84,420 133,426 (37)% Biological assets & inventories 123,954 82,524 50% Other current assets
Slide 26: Capital Structure
Capital Structure CAPITAL STRUCTURE 09-30-2025 12-11-2025 Common shares issued and outstanding 134,461,029 135,004,752 Preferred shares(1) 13,794,163 13,794,163 Options (Weighted Average Exercise Price: $10.03) 2,301,674 2,262,196 Warrants (Exercise Price: $3.65) 4,450,500 4,450,500 Top-up rights (W